Title: Minitablets: Enhancing Safety and Palatability for Pediatric Medicines
Author: Gus LaBella, Title, Mikart
Technological advancements in minitablet (MT) manufacturing, combined with an improved understanding of their palatability and ease of swallowing for children, are fueling interest in MTs as a preferred pediatric dosage form. Despite their numerous advantages in flexibility and patient compliance, MT production presents unique challenges. Collaborating with a seasoned contract development and manufacturing organization (CDMO) like Mikart is crucial for leveraging these advancements in both new drug development and life cycle management strategies.
Growing Appeal of Minitablets in Pediatric Care
Historically, most drugs were developed with adult patients in mind, often overlooking the unique requirements of children. This oversight has seen a shift in both the United States and Europe, where regulatory frameworks now mandate the development of formulations specifically for pediatric use. These regulations have propelled drug developers to seek versatile solutions that cater to the nuanced needs of children across all age groups, from infants to adolescents.
Minitablets (MTs) have emerged as a particularly promising technology in pediatric targeted formulation. Their development has been spurred by advancements in manufacturing equipment and a deeper understanding of their benefits in pediatric care — especially their ease of swallowing and improved palatability, which are crucial for acceptance by young patients.
Download to read the full article.
Download now